Health Economics and Outcomes Research & Market Access: Insights and Thought Leadership
-
July 22, 2026
-
FTI Consulting’s Center for Healthcare Economics and Policy bridges the gap between innovation and reimbursement. Our multidisciplinary team of Ph.D. economists, predictive modelers, and industry experts delivers the technical precision and strategic insight needed to justify pricing, coverage, and utilization. Our health economics and outcomes research drives thought leadership across the industry's most respected platforms. From peer-reviewed publications in leading medical and health economics journals to presentations at conferences, our work spans diverse clinical areas and cutting-edge methodologies. Explore our insights below and discover how evidence-based research shapes healthcare policy and market strategy.
Service Offerings
Policy Analysis
- Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative, Schizophrenia Research, June 2026 - (here)
- Price Isn’t Value or Cost: ICER Launch Price Report Critique, Report, February 24, 2026 - (here)
- Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”, USC Schaeffer, October 20, 2025 - (here)
- Jason Shafrin Interviewed in ‘Patti’s People’ Episode on Improving Healthcare Outcomes, The Evidence Base, October 10, 2025 - (here, free account required)
- Perspectives from the Healthcare Economist: Why CMS/AHIP’s Prior Authorization Changes Won’t Hurt Payers, The Evidence Base, July 10, 2025 - (here, free account required)
- New Commentary: Understanding a Major Change to U.S. Drug Pricing Policy, The Evidence Base, June 6, 2025 - (here, free account required)
- Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival, American Cancer Society Cancer Action Network, January 13, 2025 - (here)
- Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?, Value in Health, January 2025 - (here)
- In the News: Jason Shafrin Interviewed in The Evidence Base on GCEA User Guide, The Evidence Base, December 3, 2024 - (here, free account required)
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices, De Gruyter’s Forum for Health Economics and Policy, November 8, 2024 - (here)
- Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies, Journal of Multidisciplinary Healthcare, August 29, 2024 - (here)
- STAT News Commentary: The World is Relying on the United States to Get Value-based Drug Pricing Right, STAT, May 6, 2024 - (here)
- Podcast: Biosimilars Role in Improving Patient Access, Prescription for Better Access, February 27, 2024 - (here)
- A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE’s Size of Benefit Multiplier, Value in Health, October 2023 - (here)
- Quantifying the Long-Run Economic and Health Impact of Reduced Intellectual Property Protections for New Drugs, SSRN, May 26, 2023 - (here)
- A Strategy For Value-Based Drug Pricing Under The Inflation Reduction Act, Health Affairs Forefront, May 4, 2023 - (here)
- Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market, Whitepaper, April 26, 2023 - (here)
- The Role of Intellectual Property in the Biopharmaceutical Sector, International Federation of Pharmaceutical Manufacturers & Associations, September 21, 2022 - (here)
- Challenges in Preserving Access to Orphan Drugs Under an HTA Framework, Report, December 2, 2021 - (here)
Value Measurement
- Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives, ClinicoEconomics and Outcomes Research, July 8, 2026 - (here)
- Quantifying the lifetime economic impact of pediatric oral nutritional supplements, Clinical Nutrition ESPEN, June 2026 - (here)
- Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making, Journal of Medical Economics, January 10, 2026 - (here)
- Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States, Journal of Medical Economics, November 26, 2025 - (here)
- Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States, Blood, November 3, 2025 - (here)
- Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL, Blood, November 2025 - (here)
- Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia, Blood, November 2025 - (here)
- Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”, USC Schaeffer, October 20, 2025 - (here)
- Perspectives from the Healthcare Economist: CMS Doesn’t Consider QALYs – What’s a Health Economist To Do?, The Evidence Base, August 27, 2025 - (here)
- Cost-Effectiveness Analysis Model for Sotagliflozin Compared with Insulin Monotherapy for Patients with Type 1 Diabetes and Chronic Kidney Disease, Journal of Managed Care & Specialty Pharmacy, July 2, 2025 - (here)
- Cost Impact of Bruton’s Tyrosine Kinase Inhibitor Selection in Medicare Patients with Chronic Lymphocytic Leukemia, Journal of Comparative Effectiveness Research, January 14, 2025 - (here)
- Health Economic Value of Postacute Oral Nutritional Supplementation in Older Adult Medical Patients at Risk for Malnutrition: A US-based Modelling Approach, BMJ Open, November 22, 2024 - (here)
- Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study, Clinical Lymphoma Myeloma and Leukemia, September 2024 - (here)
- Cost–effectiveness of Sotagliflozin for the Treatment of Patients with Diabetes and Recent Worsening Heart Failure, Journal of Comparative Effectiveness Research, May 21, 2024 - (here)
- Quantifying The Value of Reduced Health Disparities: Low-Dose CT Lung Cancer Screening of High-Risk Individuals within the US, Value in Health, March 2024 - (here)
- Use of Conditionally Essential Amino Acids and the Economic Burden of Postoperative Complications After Fracture Fixation, ClinicoEconomics and Outcomes Research, October 25, 2023 - (here)
- Impact of Semaglutide 2.4 mg on Reducing Health Inequality in the US: A Modeling Study, STAT, October 17, 2023 - (here)
- Wound-Specific Oral Nutritional Supplementation Can Reduce the Economic Burden of Pressure Injuries for Nursing Homes: Results from an Economic Model, Journal of Long-Term Care, July 3, 2023 - (here)
- Economic Impact of Sequential Testing for COVID-19 and Influenza with Molecular Point of Care in 3 European Countries, ISPOR, May 15, 2022 - (here)
- Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy, Advances in Therapy, January 5, 2022 - (here)
Real-World Evidence
- Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis, Clinical Lung Cancer, November 2025 - (here)
- Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data Analysis, Blood Advances, September 23, 2025 - (here)
- Use of Real-world Evidence in the Medicare Drug Price Negotiation Program, Health Affairs Scholar, March 2025 - (here)
- Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments, The American Journal of Managed Care, December 11, 2024 - (here)
- A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria, Advances in Therapy, November 5, 2024 - (here)
- Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria, Clinical and Applied Thrombosis/Hemostasis, January 4, 2024 - (here)
- Prevalence, Treatment Patterns, and Survival by Age in Patients Diagnosed with Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Brain Metastases (BM) in the U.S., Journal of Thoracic Oncology, March 2023 - (here)
- Impact of Suboptimal or Inappropriate Treatment on Healthcare Resource Use and Cost Among Patients with Uncomplicated Urinary Tract Infection, Antimicrobial Resistance & Infection Control, November 4, 2022 - (here)
- Health Care Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis, Journal of Managed Care & Specialty Pharmacy, August 24, 2022 - (here)
- Association of Health Care Utilization and Costs with Patient-reported Outcomes in Patients with Ankylosing Spondylitis, Journal of Managed Care & Specialty Pharmacy, August 24, 2022 - (here)
- Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database, Antimicrob Resist Infect Control, June 14, 2022 - (here)
Patient-Centered Research
- Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US, Future Oncology, February 27, 2026 - (here)
- Abstract PS5-12-02: Quantifying the value of progression-free survival in breast cancer treatment among a general population of US women, AACR Journals, February 17, 2026 - (here)
- EE341 Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US?, Value in Health, December 2025 - (here)
- Patient Preferences for Attributes of Bispecific Antibodies for Relapse/Refractory Diffuse Large B-cell Lymphoma in the US, Future Oncology, October 21, 2025 - (here)
- Caregiver Risk Preferences for Delaying Loss of Ambulation in Duchenne Muscular Dystrophy in the United States, Current Medical Research and Opinion, August 27, 2025 - (here)
- Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy, The American Journal of Managed Care, January 14, 2025 - (here)
- Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy, The American Journal of Managed Care, July 10, 2024 - (here)
- Are Caregivers Ready for Digital?, SAGE Publications Ltd, March 10, 2022 - (here)
Market Access
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies, MDPI, February 6, 2026 - (here)
- A Structured Approach for Identifying Disease Analogs for Pulmonary Arterial Hypertension, Journal of Managed Care & Specialty Pharmacy, July 31, 2025 - (here)
Disease Area
Cardiovascular Disease
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies, MDPI, February 6, 2026 - (here)
- A Structured Approach for Identifying Disease Analogs for Pulmonary Arterial Hypertension, Journal of Managed Care & Specialty Pharmacy, July 31, 2025 - (here)
- Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments, The American Journal of Managed Care, December 11, 2024 - (here)
Endocrinology/Metabolism/Bone
- Cost-Effectiveness Analysis Model for Sotagliflozin Compared with Insulin Monotherapy for Patients with Type 1 Diabetes and Chronic Kidney Disease, Journal of Managed Care & Specialty Pharmacy, July 2, 2025 - (here)
- Health Economic Value of Postacute Oral Nutritional Supplementation in Older Adult Medical Patients at Risk for Malnutrition: A US-based Modelling Approach, BMJ Open, November 22, 2024 - (here)
- Cost–effectiveness of Sotagliflozin for the Treatment of Patients with Diabetes and Recent Worsening Heart Failure, Journal of Comparative Effectiveness Research, May 21, 2024 - (here)
- Use of Conditionally Essential Amino Acids and the Economic Burden of Postoperative Complications After Fracture Fixation, ClinicoEconomics and Outcomes Research, October 25, 2023 - (here)
- Impact of Semaglutide 2.4 mg on Reducing Health Inequality in the US: A Modeling Study, STAT, October 17, 2023 - (here)
Hematology/Coagulation
- Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making, Journal of Medical Economics, January 10, 2026 - (here)
- A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria, Advances in Therapy, November 5, 2024 - (here)
- Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria, Clinical and Applied Thrombosis/Hemostasis, January 4, 2024 - (here)
Infectious Disease (non-viral)
- Impact of Suboptimal or Inappropriate Treatment on Healthcare Resource Use and Cost Among Patients with Uncomplicated Urinary Tract Infection, Antimicrobial Resistance & Infection Control, November 4, 2022 - (here)
- Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database, Antimicrob Resist Infect Control, June 14, 2022 - (here)
Infectious Disease (viral)
- Economic Impact of Sequential Testing for COVID-19 and Influenza with Molecular Point of Care in 3 European Countries, ISPOR, May 15, 2022 - (here)
Neurology
- Caregiver Risk Preferences for Delaying Loss of Ambulation in Duchenne Muscular Dystrophy in the United States, Current Medical Research and Opinion, August 27, 2025 - (here)
- Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy, The American Journal of Managed Care, January 14, 2025 - (here)
- Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy Therapies, Journal of Multidisciplinary Healthcare, August 29, 2024 - (here)
- Quantifying the Insurance Value for Rare Diseases: Duchenne Muscular Dystrophy, The American Journal of Managed Care, July 10, 2024 - (here)
Oncology
- Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives, ClinicoEconomics and Outcomes Research, July 8, 2026 - (here)
- Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US, Future Oncology, February 27, 2026 - (here)
- Abstract PS5-12-02: Quantifying the value of progression-free survival in breast cancer treatment among a general population of US women, AACR Journals, February 17, 2026 - (here)
- Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States, Journal of Medical Economics, November 26, 2025 - (here)
- Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL, Blood, November 2025 - (here)
- Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia, Blood, November 2025 - (here)
- Budget impact of fixed duration acalabrutinib in combination with venetoclax in previously untreated chronic lymphocytic leukemia patients in the United States, Blood, November 3, 2025 - (here)
- Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis, Clinical Lung Cancer, November 2025 - (here)
- EE341 Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US?, Value in Health, December 2025 - (here)
- Patient Preferences for Attributes of Bispecific Antibodies for Relapse/Refractory Diffuse Large B-cell Lymphoma in the US, Future Oncology, October 21, 2025 - (here)
- Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL: A SEER-Medicare Data Analysis, Blood Advances, September 23, 2025 - (here)
- Cost Impact of Bruton’s Tyrosine Kinase Inhibitor Selection in Medicare Patients with Chronic Lymphocytic Leukemia, Journal of Comparative Effectiveness Research, January 14, 2025 - (here)
- Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival, American Cancer Society Cancer Action Network, January 13, 2025 - (here)
- Quantifying the Financial Impact of Treatment Intolerance in Chronic Myeloid Leukemia on Oncology Clinical Practices: A Mixed-Methods Study, Clinical Lymphoma Myeloma and Leukemia, September 2024 - (here)
- Quantifying The Value of Reduced Health Disparities: Low-Dose CT Lung Cancer Screening of High-Risk Individuals within the US, Value in Health, March 2024 - (here)
- Prevalence, Treatment Patterns, and Survival by Age in Patients Diagnosed with Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Brain Metastases (BM) in the U.S., Journal of Thoracic Oncology, March 2023 - (here)
- Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy, Advances in Therapy, January 5, 2022 - (here)
Psychiatry
- Reframing schizophrenia as a neurodevelopmental syndrome: The scientific and social imperative, Schizophrenia Research, June 2026 - (here)
- Are Caregivers Ready for Digital?, SAGE Publications Ltd, March 10, 2022 - (here)
Rheumatology
- Association of Health Care Utilization and Costs with Patient-reported Outcomes in Patients with Ankylosing Spondylitis, Journal of Managed Care & Specialty Pharmacy, August 24, 2022 - (here)
- Health Care Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis, Journal of Managed Care & Specialty Pharmacy, August 24, 2022 - (here)
Other
- Quantifying the lifetime economic impact of pediatric oral nutritional supplements, Clinical Nutrition ESPEN, June 2026 - (here)
- Price Isn’t Value or Cost: ICER Launch Price Report Critique, Report, February 24, 2026 - (here)
- Response to the Draft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”, USC Schaeffer, October 20, 2025 - (here)
- Jason Shafrin Interviewed in ‘Patti’s People’ Episode on Improving Healthcare Outcomes, The Evidence Base, October 10, 2025 - (here, free account required)
- Perspectives from the Healthcare Economist: CMS Doesn’t Consider QALYs – What’s a Health Economist To Do?, The Evidence Base, August 27, 2025 - (here)
- Perspectives from the Healthcare Economist: Why CMS/AHIP’s Prior Authorization Changes Won’t Hurt Payers, The Evidence Base, July 10, 2025 - (here, free account required)
- New Commentary: Understanding a Major Change to U.S. Drug Pricing Policy, The Evidence Base, June 6, 2025 - (here, free account required)
- Use of Real-world Evidence in the Medicare Drug Price Negotiation Program, Health Affairs Scholar, March 2025 - (here)
- Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?, Value in Health, January 2025 - (here)
- Response to theDraft Report of the Health Economics Methods Advisory (HEMA): “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies”, USC Schaeffer, October 20, 2025 - (here)
- In the News: Jason Shafrin Interviewed in The Evidence Base on GCEA User Guide, The Evidence Base, December 3, 2024 - (here, free account required)
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices, De Gruyter’s Forum for Health Economics and Policy, November 8, 2024 - (here)
- STAT News Commentary: The World is Relying on the United States to Get Value-based Drug Pricing Right, STAT, May 6, 2024 - (here)
- Podcast: Biosimilars Role in Improving Patient Access, Prescription for Better Access, February 27, 2024 - (here)
- A Decade of Health Innovation: The Impact of New Medicines on Patient Health and the Implications for NICE’s Size of Benefit Multiplier, Value in Health, October 2023 - (here)
- Wound-Specific Oral Nutritional Supplementation Can Reduce the Economic Burden of Pressure Injuries for Nursing Homes: Results from an Economic Model, Journal of Long-Term Care, July 3, 2023 - (here)
- Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market, Whitepaper, April 26, 2023 - (here)
- A Strategy For Value-Based Drug Pricing Under The Inflation Reduction Act, Health Affairs Forefront, May 4, 2023 - (here)
- Quantifying the Long-Run Economic and Health Impact of Reduced Intellectual Property Protections for New Drugs, SSRN, May 26, 2023 - (here)
- The Role of Intellectual Property in the Biopharmaceutical Sector, International Federation of Pharmaceutical Manufacturers & Associations, September 21, 2022 - (here)
- Challenges in Preserving Access to Orphan Drugs Under an HTA Framework, Report, December 2, 2021 - (here)
Published
July 22, 2026
Key Contacts
Senior Managing Director